The estimated Net Worth of Barry Ticho is at least $2.31 million dollars as of 3 September 2024. Barry Ticho owns over 10,000 units of Stoke Therapeutics stock worth over $184,029 and over the last 5 years he sold STOK stock worth over $1,387,188. In addition, he makes $741,090 as Chief Medical Officer at Stoke Therapeutics.
Barry has made over 18 trades of the Stoke Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of STOK stock worth $6,000 on 3 September 2024.
The largest trade he's ever made was exercising 174,027 units of Stoke Therapeutics stock on 1 June 2020 worth over $172,287. On average, Barry trades about 15,317 units every 62 days since 2020. As of 3 September 2024 he still owns at least 12,485 units of Stoke Therapeutics stock.
You can see the complete history of Barry Ticho stock trades at the bottom of the page.
Dr. Barry S. Ticho M.D., Ph.D. serves as Chief Medical Officer of the Company. From February 2016 to September 2017, Dr. Ticho served as Head of Cardiovascular and Metabolic Diseases at Moderna, Inc., a biotechnology company. From October 2013 to February 2016, Dr. Ticho served as Head of External Research and Development Innovation for the Cardiovascular and Metabolic Disease Research Unit at Pfizer, Inc., a pharmaceutical company. Previously, Dr. Ticho served as the Vice President of Clinical Development at Biogen Inc., a biopharmaceutical company. Dr. Ticho holds a B.A. in Biology from Haverford College and an M.D. and a Ph.D. in Biochemistry and Molecular Biology from the University of Chicago.
As the Chief Medical Officer of Stoke Therapeutics, the total compensation of Barry Ticho at Stoke Therapeutics is $741,090. There are 4 executives at Stoke Therapeutics getting paid more, with Stephen Tulipano having the highest compensation of $1,176,400.
Barry Ticho is 60, he's been the Chief Medical Officer of Stoke Therapeutics since 2017. There are 10 older and 9 younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics, Inc. is Dr. Edward M. Kaye M.D., Ph.D., 72, who is the CEO & Director.
Barry's mailing address filed with the SEC is C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD, MA, 01730.
Over the last 5 years, insiders at Stoke Therapeutics have traded over $49,612,288 worth of Stoke Therapeutics stock and bought 4,288,550 units worth $94,976,062 . The most active insiders traders include Group, Llc Green Jeremy Red..., Investments, Lpwong Roderic... et Trust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of $1,639,987. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth $6,000.
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Stoke Therapeutics executives and other stock owners filed with the SEC include: